Undecimal Bio lands €16 million to develop targeted RNA medicines beyond the liver

What happened

Cambridge-based Undecimal Bio, a spin-out from Eleven Therapeutics advancing targeted delivery of siRNA therapeutics, today announced a €16 million ($18 million) Seed financing round to expand DELiveri, its proprietary AI-enabled platform for identifying conjugates that can direct RNA medicines to defined cell types. The round was co-led by 4BIO Capital and IQ Capital, with participation […] The post Undecimal Bio lands €16 million to develop targeted RNA medicines beyond the liver appeared first on EU-Startups .

The round was co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital. The funding will also be used to progress Undecimal’s renovascular programmes and enable expansion of the team at their laboratories based at the Cancer Research UK Cambridge Institute.

“ The hard problem in RNAi was never the silencing, it was getting the molecule to the right cell ,” says Dr. Undecimal Bio’s Seed financing comes amid a series of European investments in RNA-based therapeutics, targeted drug delivery and AI-enabled biotechnology platforms in 2026. Related announcements include Dublin-based Aerska ‘s €32 million Series A (an early stage of company funding) to advance RNA interference medicines targeting neurological diseases, Paris-based WhiteLab Genomics ‘ €23.2 million Series B for AI-driven genomic medicine design and delivery, and Cambridge-based STORM Therapeutics ‘ €47.5 million Series C to progress RNA-modifying cancer treatments.